SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:572f8976-b34c-4ee8-bae9-b42e63e727ed"
 

Search: onr:"swepub:oai:lup.lub.lu.se:572f8976-b34c-4ee8-bae9-b42e63e727ed" > The burden of ankyl...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kobelt, GiselaLund University,Lunds universitet,Ortopedi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Orthopaedics (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine (author)

The burden of ankylosing spondylitis in Spain.

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • Elsevier BV,2008

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:572f8976-b34c-4ee8-bae9-b42e63e727ed
  • https://lup.lub.lu.se/record/1153986URI
  • https://doi.org/10.1111/j.1524-4733.2007.00252.xDOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117191721URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • OBJECTIVE: To investigate the burden of ankylosing spondylitis (AS) in Spain, as baseline for economic evaluation of the use of biological agents. METHODS: A cross-sectional retrospective observational study was performed in 601 patients with AS in Spain, using a methodology developed in studies in the United Kingdom and Canada. Patients were mailed a questionnaire asking about their health-care consumption, out-of-pocket expenses, work capacity, need for informal care during the past 3 months, as well as quality of life. Patient's current functional status and disease activity level was assessed using the Bath functional and disease activity indexes (BASFI and BASDAI). RESULTS: The mean age (median) was 47.8 (12.4) years, and the mean disease duration was 18.8 years. Eighty percent of patients were male, and slightly more than half of patients below 65 years of age were working. The mean (median) BASDAI and BASFI scores were 4.3 (2.5) and 3.8 (2.9),respectively, and all levels of disease severity were represented. The mean (median) total annual cost per patient is estimated at euro 20,328 (euro 7920). Direct health care represented 22.8%, investments (adaptations of house and devices) and informal care 43.5%, and productivity losses 33.7%. Costs increased significantly with worsening disease, in particular diminishing physical function, covering a range between euro 5000 and euro 75,000 per patient and year. The mean (median) utility was 0.59 (0.30). Utility showed a significant inverse relation with BASFI and BASDAI, covering a range from 0.80 for patients with BASFI/BASDAI below 3 to 0.25 for patients with BASFI/BASDAI greater than 7. CONCLUSIONS: As in studies in other countries, all types of costs accelerate steeply with worsening disease while utility decreases significantly, indicating the need to prevent disease progression.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sobocki, PatrikKarolinska Institutet (author)
  • Mulero, Juan (author)
  • Gratacos, Jordi (author)
  • Pocovi, Ana (author)
  • Collantes-Estevez, Eduardo (author)
  • Ortopedi, LundSektion III (creator_code:org_t)

Related titles

  • In:Value in Health: Elsevier BV11:3, s. 408-4151098-3015
  • In:Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research: Elsevier BV11:3, s. 408-4151524-4733

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view